Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 18/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4547796 | 0.88 | ELANE (0.56) | ELANECYP2C9CYP3A4 | |
| SCHEMBL13089717 | 0.82 | ELANE (0.43) | ELANECYP2C9CYP3A4ADRB1HTR1A | |
| SCHEMBL4547793 | 0.81 | ELANE (0.60) | ELANECYP2C9CYP3A4 | |
| SCHEMBL8346759 | 0.81 | ELANE (0.54) | ELANECYP2C9CYP3A4 | |
| SCHEMBL8346687 | 0.80 | SMN1; SMN2 (0.41) | ELANECYP2C9ALDH1A1MEN1KMT2A | |
| SCHEMBL2678883 | 0.79 | ELANE (0.67) | ELANECYP2C9CYP3A4 | |
| SCHEMBL2677656 | 0.78 | ELANE (0.55) | ELANECYP2C9CYP3A4 | |
| SCHEMBL4547792 | 0.75 | ELANE (0.56) | ELANECYP2C9CYP3A4 | |
| SCHEMBL13089735 | 0.75 | ELANE (0.42) | ELANECYP2C9CYP3A4ALDH1A1ADRB1 | |
| SCHEMBL4547795 | 0.74 | ELANE (0.55) | ELANECYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539710-B1 | HETEROCYCLIC DERIVATIVES | BAYER SCHERING PHARMA AG (DE) | 2010-10-27 | — | — | EP | disclosed |